Moderna to Present at the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Moderna (Nasdaq: MRNA) has announced that David Meline, CFO, and Lavina Talukdar, SVP of Investor Relations, will engage in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 11:45 a.m. ET. The event will be accessible via a live webcast on Moderna's investor website, with a replay available for 30 days after the presentation.

Over the past decade, Moderna has evolved from an mRNA research stage entity into a leader in mRNA therapeutics and vaccines, currently advancing 24 development programs across various medical fields.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that David Meline, Chief Financial Officer, and Lavina Talukdar, Senior Vice President & Head of Investor Relations, will participate in a fireside chat at the 20^th Annual Needham Virtual Healthcare Conference on April 15^th, 2021 at 11:45 a.m. ET.

A live webcast will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 13 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210409005066/en/

FAQ

When will Moderna's CFO participate in the Needham Virtual Healthcare Conference?

Moderna's CFO, David Meline, will participate in the conference on April 15, 2021, at 11:45 a.m. ET.

How can I watch the webcast of Moderna's conference participation?

You can watch the live webcast on Moderna's investor website under the 'Events and Presentations' section.

What is Moderna's current status in the biotechnology industry?

Moderna has transformed into a leading company in mRNA therapeutics and vaccines, with 24 development programs in progress.

How many programs has Moderna entered into clinical trials?

Moderna has entered 13 programs into clinical trials across various therapeutic areas.

What notable achievement has Moderna accomplished regarding COVID-19?

Moderna has authorized one of the earliest and most effective vaccines against the COVID-19 pandemic.